Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Summary:
- Volume Zscore is a recent 2 week high. A recent surge of ZScore means trading activities is accelerating at a record speed.
| MarketCap | 24.8M |
|---|---|
| PE Ratio | |
| PEG Ratio | -0.2 |
| P/B | 2.2 |
| P/S (ttm) | 1.3 |
| Earning Growth (QoQ) | |
| Revenue Growth (QoQ) | |
| Short % | 4% |
| Held by Institutions % | 11% |
| 1 Day Vol Adjusted Return | 0.7 |
| 1 Month Vol Adjusted Return | -2.9 |
| 3 Month Vol Adjusted Return | -8.8 |
| 6 Month Vol Adjusted Return | -15.6 |
| 20 Days SMA Price ZScore | -1.0 |
| 50 Days SMA Price ZScore | -1.3 |
| 12 -26 Days PPO | -6.7 |
| 1 Month Average Short Volume Ratio | 34.5 |
| 1 Day Volume Change ZScore | 3.8 |
| 1 Month Daily Vol | 4.3 |
Stock news
SAN DIEGO, May 23, 2022--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three months ended March 31, 2022 and provides a business update.
SAN DIEGO, May 16, 2022--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces a delay in the filing of its Quarterly Report on Form 10-Q for the three months ended March 31, 2022. The delay is related to the ongoing accounting review of Biocept’s financial statements as of and for the three months ended March 31, 2022, which ongoing review is a result of a change in circumstances at the U.S. Health Resources Services Administration (HR
SAN DIEGO, April 08, 2022--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 519,140 shares of its common stock to 44 new employees, including an inducement stock option to purchase 150,000 shares of its common stock to Philippe Marchand, Ph.D., its new Chief Operations Officer. The inducement stock options have a grant date of March 31, 2022, and were gr
SAN DIEGO, April 06, 2022--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and 12 months ended December 31, 2021 and provides a business update.
SAN DIEGO, March 31, 2022--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports unaudited net revenue for 2021 of $61.2 million and cash and cash equivalents as of December 31, 2021 of approximately $28 million.
SAN DIEGO, March 18, 2022--Biocept to report 2021 fourth quarter and full year financial results on March 30, 2022.